BTK and B-cell non-Hodgkin lymphoma: Bruton's tyrosine kinase (BTK) inhibitors which are approved for treatment of B cell lymphomas have the capacity to block both BCR signaling and STAT3 activation and are capable of reducing IL-10 production and PD-L1 expression in B cells (161).